Emerging pharmacotherapies in chronic rhinosinusitis with nasal polyps - PubMed
3 hours ago
- #CRSwNP
- #biologics
- #precision medicine
- Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disorder affecting sinonasal mucosa and quality of life.
- CRSwNP is characterized by T2 or non-T2 inflammatory endotypes and often coexists with asthma or aspirin-exacerbated respiratory disease.
- Emerging pharmacotherapies include targeted biologics like dupilumab, omalizumab, and mepolizumab, which show efficacy in reducing nasal polyp size and improving symptoms.
- Evidence from RCTs, meta-analyses, and real-world studies supports the clinical benefits of these biologics, though limitations exist.
- Future therapies may target upstream epithelial cytokines (TSLP, IL-33), small-molecule inhibitors, microbiome modulation, and advanced topical delivery systems.
- Challenges remain in cost, treatment duration, and patient selection, necessitating personalized management through endotype characterization and biomarkers.
- Future advances may focus on immune modulation, epithelial barrier restoration, and optimized local drug delivery for better efficacy and reduced systemic exposure.